A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
This is a Phase 1 Study Evaluating the Safety of ABT-263 in Combination with Etoposide/Cisplatin in Subjects with Small Cell Lung Cancer (SCLC).
Solid Tumors
DRUG: ABT-263|DRUG: etoposide/cisplatin
Assess the safety profile of ABT-263 when administered in combination with etoposide/cisplatin in subjects with Cancer., Weekly|Characterize the pharmacokinetics of ABT-263 when administered in combination with etoposide/cisplatin ., Weekly|Determine the maximum tolerable dose (MTD) of ABT-263 when administered in combination with etoposide/cisplatin., Weekly|Determine the recommended Phase 2 dose (RPTD) of ABT-263 when administered in combination with etoposide/cisplatin., Weekly
Evaluate preliminary data regarding progression free survival (PFS)., Bi-monthly|Evaluate preliminary data regarding objective response rate (ORR)., Bi-monthly|Evaluate preliminary data regarding time to tumor progression (TTP)., Bi-monthly|Evaluate preliminary data regarding overall survival (OS)., Bi-monthly|Evaluate preliminary data regarding duration of overall response., Bi-monthly|Evaluate preliminary data regarding Eastern Cooperative Oncology Group (ECOG) performance status., Bi-monthly|Evaluate biomarkers, Define the relationship between disease state (related to patient selection and monitoring), B-Cell Lymphoma 2 (Bcl-2) family protein expression, and potential response to the proposed therapy ABT-263 and etoposide/cisplatin., Bi-monthly
This is a Phase 1 Study Evaluating the Safety of ABT-263 in Combination with Etoposide/Cisplatin in Subjects with Small Cell Lung Cancer (SCLC).